The U.S. Food and Drug Administration has authorized the use of a digital product that relies on artificial intelligence to treat patients with chronic insomnia, Boston-based Pear Therapeutics said Thursday.
The company’s product, called Somryst, uses a smartphone or tablet to deliver therapeutic recommendations to patients, such as when they should go to bed and rise, and how to identify and control behavioral patterns that may interfere with sleep.
About the Author Reprints
